Importantly, a GLP‐1 receptor agonist has shown good protective and disease‐modifying effectsin PD patients as shown in reduced disease progression even 3 months after drug administration had stopped (Athauda et al., 2017), and improvement of growth‐factor signaling in the brain (Athauda et al., 2019). This evidence concerns the gene GLP1R and Parkinson disease.